文献速递鼻科头颈外科

多中心评估:纯内镜下经鼻入路治疗53例嗅神经母细胞瘤

Multicenter assessment of exclusive endoscopic endonasal approach for the treatment of 53 olfactory neuroblastomas.
PubMed 文献 · Head Neck · 2018-01-22

基于法国REFCOR数据库的53例嗅神经母细胞瘤患者,均接受纯内镜下经鼻手术(49%联合颅底切除与修复),5年总生存率87%、无病生存率71%,并发症率18.8%,切缘阳性率26.8%但未影响生存,结论认为纯内镜治疗有效可靠。

要点

  • 纯内镜下经鼻入路治疗嗅神经母细胞瘤可行且可靠。
  • 5年总生存率87%,无病生存率71%。
  • 切缘阳性率26.8%但未显著影响生存。

核心结论

  • 纯内镜下治疗在大样本对照系列中显示有效且可靠。

研究设计与样本

  • 多中心协作研究,纳入法国REFCOR数据库53例嗅神经母细胞瘤患者(16例T1、8例T2、19例T3、10例T4),均行纯内镜下手术,26例(49%)联合颅底切除与修复,未行外部开颅。

主要发现

  • 5年总生存率为87%,无病生存率为71%,平均随访45.4±26.5个月。
  • 并发症发生率为18.8%,其中4例为脑膜炎。
  • 病理分析显示切缘阳性率为26.8%,多见于硬脑膜和眶骨膜,但未影响总生存或无病生存。
  • 预防性颈部照射似乎可降低复发率。

临床怎么用

  • 对于嗅神经母细胞瘤,可考虑纯内镜下经鼻入路作为有效治疗方式,必要时联合颅底切除与修复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the particularities of olfactory neuroblastoma (ONB) and the lack of studies on the subject, a multicenter collaborative study was conducted to assess treatment strategy. METHODS: Fifty-three patients with ONB were included from the French Rare Head and Neck Cancer Expert Network (REFCOR) database: 16T1, 8T2, 19T3, and 10T4. All cases were treated endoscopically with skull base removal and repair in 26 cases (49%) and without external craniotomy. RESULTS: The overall survival (OS) and disease-free survival (DFS) rates at 5 years were 87% and 71%, respectively, with mean follow-up of 45.4 ± 26.5 months. The complication rate was 18.8% with 4 cases of meningitis. Pathological analysis showed positive margins in 26.8%, notably on the dura-mater and periorbita, without impairment of OS or DFS. Forty-eight patients received adjuvant radiotherapy on T ± N. Ten patients had a recurrence (18.9%). Six patients died of their disease. Prophylactic neck irradiation seemed to reduce the recurrence rate. CONCLUSION: Exclusively endoscopic treatment proved efficient and reliable in a large controlled series.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. de Gabory L, Verillaud B, Rumeau C, et al. Multicenter assessment of exclusive endoscopic endonasal approach for the treatment of 53 olfactory neuroblastomas. Head Neck. 2018. PMID: 29356209. doi:10.1002/hed.25064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。